Across Global Alliance Chooses Wemedoo's Oomnia as Central Infrastructure for Clinical Trials

In a significant move towards enhancing the efficiency of clinical trial management, Across Global Alliance has selected Wemedoo's oomnia® as its centralized digital infrastructure. This strategic partnership aims to optimize clinical trials across more than 90 countries, ensuring seamless integration, regulatory compliance, and real-time collaboration among its members.

Across Global Alliance is a coalition of clinical research organizations (CROs) and specialist service providers dedicated to delivering comprehensive clinical research services. The alliance focuses on integrating regional expertise and offers a unified operational framework to facilitate better coordination and data integrity across diverse therapeutic areas.

Why Oomnia?

After a thorough evaluation of various solutions available on the market, Wemedoo's Oomnia stood out as the only system capable of addressing the complex operational requirements of the alliance. The platform integrates crucial clinical trial functions, such as Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), Randomization and Trial Supply Management (RTSM), and electronic Trial Master Files (eTMF) into a single cohesive interface. This integration is vital for eliminating inefficiencies that arise from fragmented systems and disjoined data workflows, ultimately enhancing operational effectiveness.

Steven Bukvic, Chairman of the Across Global Alliance, emphasized the importance of having a robust system that promotes seamless collaboration among global teams. He stated, “Running global clinical trials necessitates a system that enhances collaboration, reduces delays, and ensures data consistency across all operational sites. Oomnia fulfills these demands with a commitment to maintain compliance and provide operational flexibility.”

Benefits of Oomnia

By adopting Oomnia as its digital backbone, Across Global Alliance positions itself to significantly improve clinical trial execution for its clients and members. The platform allows for real-time data quality reviews, ensuring that all stakeholders can access essential information almost instantaneously. Additionally, the user-friendly interface of the platform makes it easier for users to navigate through various functionalities, thereby streamlining workflow processes.

“Partnering with Across Global Alliance marks an important milestone in our journey to revolutionize clinical trial management,” said Nina Cihoric, CEO of Wemedoo AG. “Our aim is to provide an incredibly integrated and adaptive system that allows alliance members to direct their efforts toward scientific advancement rather than getting bogged down by administrative issues.”

What's Next for Across Global Alliance?

As this partnership unfolds, both parties are optimistic about leveraging Oomnia to transform the landscape of clinical trial management. With the continuous evolution of medical research and the pressing need to streamline operations, the integration of such advanced systems is crucial. The commitment to enhancing operational excellence in clinical research will allow Across Global Alliance to not only meet the current demands but also innovate for future challenges.

About Across Global Alliance

Founded in Singapore, the Across Global Alliance combines the strengths of various CROs and specialist service providers on a global scale. With a focus on innovative clinical research methodologies, the alliance strives to provide quality services that assure data integrity and operational excellence.

About Wemedoo AG

Wemedoo AG is a Swiss firm specializing in healthcare data-driven solutions. The company merges cutting-edge technology with clinical expertise to enable research teams and sponsors to conduct and manage clinical trials more effectively and efficiently, thereby reducing costs and expediting medical innovations.

In conclusion, the selection of Wemedoo's Oomnia as the central infrastructure for clinical trials not only symbolizes a strategic alliance but also represents a pivotal moment for enhancing operational capabilities within the clinical research domain.